206 related articles for article (PubMed ID: 21450690)
21. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma.
Tannapfel A; Sommerer F; Benicke M; Weinans L; Katalinic A; Geissler F; Uhlmann D; Hauss J; Wittekind C
J Pathol; 2002 Aug; 197(5):624-31. PubMed ID: 12210082
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of Wnt signaling induces cell apoptosis and suppresses cell proliferation in cholangiocarcinoma cells.
Zhang KS; Zhou Q; Wang YF; Liang LJ
Oncol Rep; 2013 Sep; 30(3):1430-8. PubMed ID: 23799613
[TBL] [Abstract][Full Text] [Related]
23. [Induction of SMYD3 by hepatitis B virus X gene in HepG2 cells].
Yang L; Ren J; He J; Chen LB
Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):297-300. PubMed ID: 19403031
[TBL] [Abstract][Full Text] [Related]
24. Association of downregulation of WWOX with poor prognosis in patients with intrahepatic cholangiocarcinoma after curative resection.
Huang C; Tian Y; Peng R; Zhang C; Wang D; Han S; Jiao C; Wang X; Zhang H; Wang Y; Li X
J Gastroenterol Hepatol; 2015 Feb; 30(2):421-33. PubMed ID: 25168293
[TBL] [Abstract][Full Text] [Related]
25. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF.
Zou JN; Wang SZ; Yang JS; Luo XG; Xie JH; Xi T
Cancer Lett; 2009 Jul; 280(1):78-85. PubMed ID: 19321255
[TBL] [Abstract][Full Text] [Related]
26. Malignant transformation of the cultured human normal biliary tract epithelial cells induced by hepatitis C virus core protein.
Chen RF; Li ZH; Liu RY; Kong XH; Tang QB; Wang J
Oncol Rep; 2007 Jan; 17(1):105-10. PubMed ID: 17143485
[TBL] [Abstract][Full Text] [Related]
27. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas.
Zhong S; Yeo W; Tang MW; Wong N; Lai PB; Johnson PJ
Clin Cancer Res; 2003 Aug; 9(9):3376-82. PubMed ID: 12960125
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
29. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma.
Schagdarsurengin U; Wilkens L; Steinemann D; Flemming P; Kreipe HH; Pfeifer GP; Schlegelberger B; Dammann R
Oncogene; 2003 Mar; 22(12):1866-71. PubMed ID: 12660822
[TBL] [Abstract][Full Text] [Related]
30. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma.
Yeo W; Wong N; Wong WL; Lai PB; Zhong S; Johnson PJ
Liver Int; 2005 Apr; 25(2):266-72. PubMed ID: 15780049
[TBL] [Abstract][Full Text] [Related]
31. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
[TBL] [Abstract][Full Text] [Related]
32. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
[TBL] [Abstract][Full Text] [Related]
33. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines.
Harada K; Toyooka S; Maitra A; Maruyama R; Toyooka KO; Timmons CF; Tomlinson GE; Mastrangelo D; Hay RJ; Minna JD; Gazdar AF
Oncogene; 2002 Jun; 21(27):4345-9. PubMed ID: 12082624
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
[TBL] [Abstract][Full Text] [Related]
35. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway.
Goeppert B; Konermann C; Schmidt CR; Bogatyrova O; Geiselhart L; Ernst C; Gu L; Becker N; Zucknick M; Mehrabi A; Hafezi M; Klauschen F; Stenzinger A; Warth A; Breuhahn K; Renner M; Weichert W; Schirmacher P; Plass C; Weichenhan D
Hepatology; 2014 Feb; 59(2):544-54. PubMed ID: 24002901
[TBL] [Abstract][Full Text] [Related]
36. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
37. A zebrafish model of intrahepatic cholangiocarcinoma by dual expression of hepatitis B virus X and hepatitis C virus core protein in liver.
Liu W; Chen JR; Hsu CH; Li YH; Chen YM; Lin CY; Huang SJ; Chang ZK; Chen YC; Lin CH; Gong HY; Lin CC; Kawakami K; Wu JL
Hepatology; 2012 Dec; 56(6):2268-76. PubMed ID: 22729936
[TBL] [Abstract][Full Text] [Related]
38. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.
Koga Y; Kitajima Y; Miyoshi A; Sato K; Kitahara K; Soejima H; Miyazaki K
Ann Surg Oncol; 2005 May; 12(5):354-63. PubMed ID: 15915369
[TBL] [Abstract][Full Text] [Related]
39. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis.
Peters I; Rehmet K; Wilke N; Kuczyk MA; Hennenlotter J; Eilers T; Machtens S; Jonas U; Serth J
Mol Cancer; 2007 Jul; 6():49. PubMed ID: 17634119
[TBL] [Abstract][Full Text] [Related]
40. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma.
Murray PG; Qiu GH; Fu L; Waites ER; Srivastava G; Heys D; Agathanggelou A; Latif F; Grundy RG; Mann JR; Starczynski J; Crocker J; Parkes SE; Ambinder RF; Young LS; Tao Q
Oncogene; 2004 Feb; 23(6):1326-31. PubMed ID: 14961078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
